CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Shares	Additional paid-in capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023		143,833
Beginning balance at Dec. 31, 2023	$ 377,954	$ 1,200,218	$ 120,788	$ (730)	$ (942,322)
Increase (Decrease) in Stockholders' Equity
Purchases of common shares under Share Repurchase Plan (in shares)		(2,374)
Purchases of common shares under Share Repurchase Plan	(13,370)	$ (13,370)
Issuance of common shares from exercise of stock options and vesting of restricted stock units and performance awards (in shares)		2,231
Issuance of common shares from exercise of stock options and vesting of restricted stock units and performance awards	28	$ 21,134	(21,106)
Share-based compensation	5,737		5,737
Unrealized loss on available-for-sale securities	(124)			(124)
Net income (loss)	(10,749)				(10,749)
Ending balance (in shares) at Mar. 31, 2024		143,690
Ending balance at Mar. 31, 2024	$ 359,476	$ 1,207,982	105,419	(854)	(953,071)
Beginning balance (in shares) at Dec. 31, 2024	140,883	140,883
Beginning balance at Dec. 31, 2024	$ 377,478	$ 1,187,696	126,999	(647)	(936,570)
Increase (Decrease) in Stockholders' Equity
Purchases of common shares under Share Repurchase Plan (in shares)		(5,807)
Purchases of common shares under Share Repurchase Plan	$ (47,400)	$ (47,400)
Issuance of common shares from exercise of stock options and vesting of restricted stock units and performance awards (in shares)	59	2,671
Issuance of common shares from exercise of stock options and vesting of restricted stock units and performance awards	$ 355	$ 22,966	(22,611)
Share-based compensation	(3,409)		(3,409)
Unrealized loss on available-for-sale securities	(178)			(178)
Net income (loss)	$ 23,344				23,344
Ending balance (in shares) at Mar. 31, 2025	137,747	137,747
Ending balance at Mar. 31, 2025	$ 350,190	$ 1,163,262	$ 100,979	$ (825)	$ (913,226)